Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Updated Altuviiio Label With Expanded Pediatric Data Confirming Highly Effective Bleed Protection in Children With Hemophilia
The US Food and Drug Administration (FDA) has updated the label for Altuviiio® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]...
High Telehealth Use Tied to Increased Health Care Utilization, Cost
Higher telehealth use in a hospital service area is tied to increased health care utilization and cost, according to a study published online May 13 in JAMA...
Heatwave Exposure Linked to Considerable Mortality Burden
Heatwaves are associated with a considerable mortality burden, with geographic disparities apparent, according to a study published online May 14 in PLOS...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using...
U.S. Drowning Deaths Rising Again After Years of Decline
Following decades of declines, drowning deaths are once again climbing in the United States, new government data shows. More than 4,500 people died from...
About 8,000 Women Per Month Are Getting Abortion Pills Despite Their States' Bans
While some states have moved to severely curb women's access to abortion, including abortion pills, over 8,000 women living in those states are getting...
Child Maltreatment Linked to Externalizing, Internalizing Behavior
Child maltreatment is associated with increases in externalizing and internalizing behaviors, according to a study published online May 14 in Pediatrics. Anneke...
Summer of 2023 Was Hottest in 2,000 Years
High temperatures across the Northern Hemisphere last summer were scorching and frequent enough to make it the hottest summer in two millennia, new research...
San Francisco Set to Ban 'Forever Chemicals' in Firefighter Gear
San Francisco is on the verge of passing a ban on "forever chemicals" in the protective clothing firefighters wear while battling blazes. City lawmakers...
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
SHANGHAI, May 13, 2024, Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study...
FDA Safety Communication: Do Not Use Cue Health’s COVID-19 Tests Due to Risk of False Results
The U.S. Food and Drug Administration (FDA) is warning home test users, caregivers, and health care providers not to use Cue Health’s COVID-19 Tests...
Geisinger enrolls first patient in amyloid cardiomyopathy trial
DANVILLE, Pa., May 10, 2024. Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac...
There's a New Set of COVID Variants Called FLiRT: What You Need to Know
The virus behind COVID has mutated again, this time producing variants nicknamed FLiRT, the U.S. Centers for Disease Control and Prevention (CDC) has reported. The...
Recently Added
Recently added consumer and prescribing information: Myhibbin, Rezenopy, Libervant, Beqvez, Xolremdi, Pivya, Xromi, Risvan, Voydeya, Winrevair
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Myhibbin Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection.
- Libervant Libervant (diazepam) is a buccal film formulation of the benzodiazepine diazepam that may be given to treat children aged 2 to 5 years with...
- Xolremdi Xolremdi (mavorixafor) is a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...